Skip to content Skip to footer
Subscribe Now

NEWS

AbbVie to Acquire Apogee Therapeutics for ~$10.9B
Shots: AbbVie entered into a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, at a total equity value of approximately $10.9B. The transaction is expected to close in Q3’26, subject to shareholder and regulatory approvals The acquisition strengthens AbbVie’s immunology portfolio by adding Apogee’s clinical-stage pipeline focused on inflammatory and immunological…
June 22, 2026
Murj Expands Commercial Operations Across Australia and New Zealand for Cardiac Device Management Solutions
Shots: Murj announced the commercial launch of its cardiac device management platform in Australia and expanded availability in New Zealand, following its participation at the CSANZ/HRS Advances in Pacing and Conduction System Pacing Summit in Melbourne The expansion enables healthcare providers across the region to access Murj’s cloud-native solutions for cardiac implantable electronic device (CIED)…
June 22, 2026
BioArctic and Lilly Sign Research and Collaboration Agreement ~$800M to Advance Neurodegenerative Disease Therapy
Shots: BioArctic entered a research and collaboration agreement with Eli Lilly and Company to develop a potential treatment for neurodegenerative diseases by combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate Under the agreement, BioArctic will generate a new drug candidate incorporating its BrainTransporter platform, while Lilly will assume full responsibility for the…
June 22, 2026
Insilico Medicine and SK Biopharmaceuticals Sign AI-Driven Drug Discovery Deal Worth Up to $2.5B for Neuroimmune Disorders
Shots: Insilico Medicine and SK Biopharmaceuticals entered a research and development collaboration to discover AI-enabled therapies for neuroimmune disorders of the central nervous system (CNS), including neuroinflammatory, neurodegenerative, and rare neurological diseases Under the agreement, Insilico will utilize its proprietary Pharma.AI platform, covering target validation, generative chemistry, and molecule optimization, alongside its preclinical drug discovery…
June 22, 2026
MoonLake Reports Positive Week 52 P-III (VELA) Data for Sonelokimab in Hidradenitis Suppurativa (HS)
Shots: MoonLake Immunotherapeutics reported positive 52 Wks. (n=396) results from the P-III (VELA-1) and (VELA-2) studies, demonstrating durable efficacy of sonelokimab in adults with moderate-to-severe HS At Week 52, 67.2% of pts. achieved HiSCR75, 33.1% achieved HiSCR100, and 26.0% reached inflammatory remission (IHS4-100). Sonelokimab also showed substantial improvements in quality of life and pain reduction,…
June 22, 2026
Danone to Acquire MADE Group to Strengthen Healthy Nutrition Portfolio in APAC
Shots: Danone entered definitive agreements to acquire MADE Group and the remaining 49% stake in its Australian fresh dairy joint venture with Saputo Dairy Australia, expanding its footprint in the APAC healthy nutrition market MADE’s portfolio includes health-focused products such as high-protein ready-to-drink beverages, gut-health yoghurts, and coconut-based products. The Australia-based company generated sales of…
June 22, 2026
Takeda Partners with Boltz to Advance AI-Driven Drug Discovery
Shots: Boltz has partnered with Takeda to deploy its biomolecular AI platform across Takeda’s research organization, providing discovery teams access to proprietary foundation models, incl. BoltzMol-1 & BoltzProt-1, to accelerate AI-driven drug discovery The platform is designed to support in-silico molecular design, enabling structure prediction, affinity estimation, and generative design to enhance AI-driven drug discovery…
June 19, 2026
Voro Therapeutics and Alloy Therapeutics Partner on Next-Generation T-Cell Engagers
Shots: Voro Therapeutics & Alloy Therapeutics have entered into a strategic research collaboration to discover and develop next-generation masked T-cell engager (TCE) therapies Partnership will combine Voro’s PrimeBody platform with Alloy’s optimized CD3 antibodies & multispecific engineering capabilities to develop novel immunotherapies designed to selectively activate immune responses within tumors PrimeBody is designed to unlock difficult-to-target…
June 19, 2026
Load more